SBIR/STTR Research Award

Parallel Assays for Anti-Ro Peptide Diagnostics

Award identifier dd07a6cc4b9d6daa26ce99058af65908e8535a825e63175b6d840cf7785fb279Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$175,000

Program and phase

STTR · Phase I

Award year

2003

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
JK AUTOIMMUNITY, INC.
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
Not reported
Topic code
Not reported

Research abstract

DESCRIPTION (provided by the applicant): Diagnosis of rheumatic diseases is inefficient, time consuming, and frustrating. Indeed, many patients suffer unnecessarily. We wish to develop a parallel assay system for the serology of autoimmune rheumatic diseases involving multiple analytes (on the order of 1,500 per assay performed) by concentrating upon the anti-Ro autoantibody system. Anti-Ro is associated with systemic lupus erythematosus, Sjogren's syndrome, subacute acute cutaneous lupus, congenital complete heart block, and neonatal lupus dermatitis. In addition, up to 1% of the adult female population has developed these autoantibodies. Anti-Ro autoantibodies are clearly very important. The details of the fine specificity of anti-Ro have great potential to provide information that can help provide diagnostic insight, prognostic evaluation, and assess disease risk. This project has three goals. First, we will adapt anti-Ro detection to a new technology. Second, we will attempt to reproduce our previous data with the new technology. Third, we will exploit the efficiencies of the new technology to much more completely define anti-Ro fine specificity and to use the aggregate data to design useful new products. We will adapt existing technology to detect antibodies against the particular epitopes of Ro, using fiber optic microspheres in parallel array. Compared to currently employed methods, this technology will allow as much as a 1,000-fold increase in throughput, a 1,500-fold decrease in reagents and serum required for assay, and a 500-fold decrease in per analyte cost. Preliminary data have identified a putative initial epitope in the anti-Ro autoimmune response and show a close immunologic relationship to a possible etiologic agent. We will explore the advantages of this technology to reveal the relationships between peptide-defined epitopes of Ro and putative precursor antigens, the progression of the autoimmune response, and the disorders associated with anti-Ro with the hope of developing commercially useful new diagnostics, in addition to the obvious research opportunities that understanding these relationships would offer.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.